Format

Send to

Choose Destination
Int J Tuberc Lung Dis. 2016 Dec 1;20(12):38-41. doi: 10.5588/ijtld.16.0069.

TB Alliance regimen development for multidrug-resistant tuberculosis.

Author information

1
The Global Alliance for TB Drug Development (TB Alliance), New York, New York, USA.

Abstract

The recent approval of new tuberculosis (TB) drugs raises hope for new and more effective anti-tuberculosis treatment regimens. The Global Alliance for TB Drug Development (TB Alliance) is committed to ensuring that new anti-tuberculosis drugs fulfill the needs of patients, their families and the local health services that serve the communities. Here we present highlights of the TB Alliance's pipeline of regimen development, with novel regimens for patients with drug-susceptible, multidrug-resistant and extensively drug-resistant TB. The ongoing clinical trials (STAND, NC-005, Nix-TB and LIN-CL001) are outlined and their rationale and goals presented.

PMID:
28240571
DOI:
10.5588/ijtld.16.0069
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center